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Ovarian cancer is the most common type of cancer worldwide among women, 
and it is usually diagnosed at an advanced stage. The initial treatment for ovarian 
cancer is surgical debulking, but this is only effective in the treatment of early stage 
disease. Surgery alone is insufficient for treatment of advanced disease and sys-
temic therapies, in particular chemotherapies, are indicated. The main aim of this 
book chapter is to review the role of nano-therapy in treatment of advance ovarian 
cancer, in comparison to the use of traditional chemotherapies. Nano-therapies are 
thought to have advantages in terms of improving drug stability in the human body, 
chemotherapy toxicity profile, and drug delivery to the target cells thus enhancing 
drug penetration into the cancer cells. This book chapter also covers the develop-
ment of nano-therapy and also the type of potential cargos. In summary, the types 
of nanocarrier, and their roles ovarian cancer diagnosis and treatment will be 
discussed.
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1. Introduction
Although ovarian cancer represents only 5% of all cancer cases among women, 
it is ranked fifth for cancer deaths among women [1]. It is the most common among 
gynecological cancers and ranks third after uterine and cervical cancer, as it repre-
sents the highest, worst warning, and highest mortality rates [2]. Ovarian cancer, in 
particularly high grade serous subtype, is often regarded as systemic disease. I think 
you need to re-do this statement as up to 75% of OC is diagnosed at an advanced 
stage – stage III and IV. It is expected that in the next twenty years, the death rate 
of this type of cancer will increase significantly, the reason for the high death rate 
is that the disease grows secretly and without symptoms, the appearance of symp-
toms is delayed, and the lack of appropriate examination that detects the disease at 
certain stages, and this is why it is called the silent killer [3, 4].
Until recently, methods of prevention and early detection of ovarian cancer 
did not achieve satisfactory results, partly due to its heterogeneous nature [5]. In 
the past, ovarian cancer prevention methods were characterized by modifying 
risk factors and creating protective factors. Unfortunately, these modifications did 
not significantly reduce the incidence of the disease [6]. The initial treatment of 
ovarian- either with upfront cytoreductive surgery or chemotherapy (neoadjuvant) 
followed by interval debulking surgery, Almost the main reason behind recurring 
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Figure 1. 
Examples of some nanocarriers employed in therapy and diagnosis.
ovarian cancer Is due to the aggressive nature of the disease and unfortunately all 
metastatic ovarian cancer will develop resistance to conventional systemic thera-
pies, and it is known that cancer cells develop resistance especially through certain 
mechanisms such as reduced absorption, increasing elimination, inactivation/
detoxification of drugs, and accelerating DNA repair [7, 8].
Currently, many new approaches have been developed to improve delivery of 
drug to the target cancer cells, including the use of nanotechnology, and may be 
one of the solution to overcome the obstacles in treating advance ovarian cancer, 
nanotechnology was found to have extensively investigated for molecular imag-
ing, drug delivery, treatment and tumor targeting [9, 10]. In addition, this type of 
nano-based drug can overcome the systemic toxicity towards normal cells as well 
as the toxicological effects of conventional chemotherapy, In addition, it is possible 
through this technique to control the systemic toxicity of normal cells and reduce 
the toxicity of chemotherapy agents. Thus the new method can be followed by 
using multiple chemotherapeutic drugs with a suitable nanocarrier as a solution 
for the future of cancer treatment. Of course, this can be done by passive targeting 
and active targeting where both methods are used to ensure a certain and specific 
targeting of cancer cells [11, 12].
2. Nanotechnology application
Nanotechnology can be defined as a practical application that results in a process 
or product based on the single or multi-component nanoscale, which is a fairly 
recent field, nanoscale components having at least one dimension in the size range 
of 1–100 nm. This technology is referred to in the field of biology, nanobiotechnol-
ogy and in the medical field of nanomedicine, and the main principle of nanotech-
nology is to increase the effectiveness of the techniques used in the diagnosis and 
treatment of cancer.
Due to the lack of early diagnosis and the vague and multiple methods in clini-
cal procedures for detecting ovarian cancer, there are many attempts that would 
modify the course in this area, which is the use of nanotechnology and its platforms.
2.1 Nanocarriers
They are the same nanomaterials used in treatment and diagnosis, Nanocarriers 
are a multifunctional compound that can be loaded with several types of molecules 
through physical absorption and chemical conjugations reactions including drugs, 
imaging agents, targeting moieties such as ligands or antibodies, and polyethylene 
glycol. There are several types, including liposomes, micelles, and dendrimers 
(Figure 1) [13].
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Nanocarriers can be used as an alternative to conventional chemotherapy for 
drug delivery because they have many advantages, including the delivery of poorly 
soluble drugs, as they surround them within the hydrophobic interfaces or act as 
carriers for them in the blood, reduce the systemic toxicity of chemical treatments, 
regulate the stability of drugs by prolonging their existence In the blood circulation 
and protecting it from disruption and reducing the renal clearance, reducing drug 
resistance by targeting cancer cells, where nanocarriers are taken up by the method 
of endocytosis [14, 15].
2.1.1 Liposomes
Liposomes have multiple properties as they are characterized by the presence of 
two parts, an inner hydrophilic part and an outer hydrophobic part, and of course 
in the form of a lipid bilayer, and it is also possible to modify the polar heads of 
these particles. This arrangement makes it easy to include various hydrophilic and 
hydrophobic drugs in the liposomes as well as to load various drugs.
They are delivery compounds that serve greatly in enhancing the efficiency 
of pharmaceutical components, as these compounds can hide from the immune 
system, simulate biological membranes, increase the chance of a drug remaining 
for a longer period until it reaches its destination, serve to help solubilize highly 
lipophilic drug molecules or, modulate the pharmacokinetics and biodistribution of 
the API—thereby helping to minimize side effects and enhance the product safety 
profile [16, 17].
2.1.2 Dendrimers
Dendrimers are radially symmetric molecules with a well-known structure 
that are homogeneous and monodisperse structure by tree-like arms or branches, 
they are hyperbranched macromolecules with a carefully tailored architecture, the 
end-groups, which can be functionalized, thus modifying their physicochemical 
or biological properties. Dendrimers have gained a broad range of applications in 
supramolecular chemistry, particularly in host-guest reactions and self-assembly 
processes. They are highly defined artificial macromolecules, which are charac-
terized by a combination of a high number of functional groups and a compact 
molecular structure [18].
2.1.3 Micelles
This type of nanocomposite has gained very great importance as it has been well 
studied in the diagnosis and treatment of tumors. These interesting nanostructures 
comprise of spherically shaped, self-assembled amphiphilic block co-polymers 
made up of a hydrophobic core and a hydrophilic corona in an aqueous medium, 
with a diameter between 10 and 100 nm. The core of the micelle can accommodate 
hydrophobic drugs [19].
Polymeric micelles are gaining popularity as drug delivery systems because 
they not only provide increased solubility, but they also may enhance the stability 
of their drug cargo, in addition to providing in vivo pharmacokinetic advantages 
compared with the free drug [20].
2.1.4 Carbon nanotube
After discovering this nanotransmitter, it has enjoyed very great interest in 
the medical fields due to its unique structure and properties in terms of It has a 
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large surface area, large aspect ratio, nanoscale size stability and multiple chemi-
cal functions and they are especially important as carriers for transporting drugs 
and biomolecules. In this regard, this type has been used due to the functional 
properties it possesses as an important transporter for the delivery of anti-cancer 
drugs and many proteins and genes. Likewise, to directly kill cancer cells, it was 
used as a carrier for photothermal therapy (PTT) and photodynamic therapy 
(PDT) [21, 22].
3. Diagnosis and imaging
In recent times, there have been many improvements and major developments 
in the field of diagnosis and imaging with the help of nanotechnology, where it has 
been used the technologies of biosensors and point of care systems as well as the 
updated and improved imaging technologies as well as the integration of bioinfor-
matics together with multiplexed assays. At present, there are many nanoparticle 
platforms and microelectromechanical systems to strengthen and improve diagnos-
tic processes, largely as a means of diagnosing biomarkers and of course by enhanc-
ing the contrast agents used in imaging [23]. And the real mechanics of the imaging 
agent used to improve visualization and accumulation within the target cells in 
many imaging mechanisms on its subtype. There are different imaging methods 
that use imaging agents such as Optical Imaging, X-ray Imaging, positron emission 
tomography (PET), Magnetic resonance imaging (MRI) [24].
3.1 Targeted imaging agents
Targeted contrast agents are placed in a specific type of tissue or cellular recep-
tors, including certain types, such as target agents designated for imaging fibrin, 
which are molecules associated with fibrin, which are molecules associated with 
fibrin, and other molecules to track stem cells from super magnetic iron oxide, 
and there are others for imaging angiogenesis, which are of the multimodal type 
of carbon fluorinated, liposomes are used to target the sclerotic components, 
and to visualize transplant rejection, microscopic bubbles were used in MRI and 
ultrasound [25].
3.2 Activatable imaging agents
There are many nanoparticles that are actually designed to have better perfor-
mance and are imaging agents called operable molecular probes that can produce 
a signal or some kind of change that can be recorded or detected, for example, 
when enzymatic activity or a specific response to important chemical reactions, 
Two imaging technologies are combined into a single activatable lifetime imaging 
agent. This is applied by combining the high specificity of luminescence lifetime 
imaging with the high signal-to-background ratio of activatable fluorescence 
imaging [26].
3.3 Nano-liposomal imaging agents
Liposomes can encapsulate biomolecules that are hydrophilic and increase 
their internalization and solubility through the lipid bilayers of the cells, Among 
the drawbacks that can occur in the case of imaging by means of high elimination 
agents and low systemic retention degrees, and because the rapid removal process 
from the bloodstream or the body reduces the period and efficiency of imaging, 
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so it is necessary to add a molecule that increases the efficiency of imaging, and 
this is done by encapsulating the imaging agent with a liposome, can leverage the 
enhanced permeability and retention (EPR) effect seen in tumors [27, 28].
4. Fluorescent images and guided surgery
To increase the sensitivity, efficiency and strength of the imaging techniques 
used with surgery and increase their clinical efficiency, there is an actual need to 
develop new material, Therefore, many fluorescent nanoparticles essential for 
Image-supported surgeries were developed, tested and designed and tested in 
preclinical surgery there are some examples of that:
1. CF800 liposomes: This type is used to encapsulate iohexol contrast agent and is 
commercially available with clinically approved indocyanine green at ratio of 
1000: 1 (iohexol to indocyanine green).
2. magnetic iron oxide nanoparticles: A HER - 2 particle that can be combined 
with optical magnetic resonance imaging. It is a targeting ligands. I learned a 
rare near-infrared dye called NIR-830 while magnetic iron oxide nanoparticles 
provide MRI contrast.
3. Porphyrin-lipoprotein mimicking nanoparticle: This type is based on the 
formation of a nanoscale in which several techniques are combined, photody-
namic therapy, fluorescence imaging, positron emission tomography, where 
the size of the nanoparticle is 20 nanometers.
4. Fluorescent gold nanoparticles: This type is based on CT and fluorescent 
imaging platform an iodine based contrast agent is combined with aptamer 
with nucleolin specific targeting functions.
5. conjugated dendrimers: In this type activatable cell penetrating peptides are 
used Dendrimeric encapsulation and marker with gadolinium and Cy5 and 
sensitive in vivo to MMP-9 and MMP-2.
5. Nanoparticle therapeutics (anti-cancer)
Usually, nanoparticle treatments consist of therapeutic lines such as small-
molecule drugs as well as peptides, nucleic acids, proteins, and other components 
or compounds that combine with them to form nanoparticles. As we previously 
knew that nanoparticles have a direct, targeted and improved anti-cancer effect 
compared to conventional treatments. This is owing to more specific targeting 
to tumor tissues via improved pharmacokinetics and pharmacodynamics, and 
active intracellular delivery. These properties depend on the size and surface 
properties (including the presence of targeting ligands) of the nanoparticles 
(Figure 2) [29].
5.1 Nanoparticle size
Naturally, the size of the anti-cancer nanoparticles should be between 10 and 
100 nm. This measurement is based on the rates of glomerular sieving of the 
capillary wall of the kidneys. Research has indicated on size estimates where the 
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minimum is 10 nanometers as a threshold for renal excretion and where it is known 
that vessels in tumor cases are subject to leak Macromolecules in a certain way, so 
the nanoparticles should not be able to circulate for a long time in the bloodstream 
and have a chance to reach the bloodstream through the vessels of the tumor tissue 
and enter the tumor tissue where the size of the nanoparticles is greater than 
6–12 nm, which is the diameter of the sieve in the blood vessels of normal tissues 
and It is prevented from entering and not damaging the normal tissue, and it is 
known that the diameter of the sieve in the tumor blood vessels ranges from 40 to 
200 nm (Figure 3) [30].
5.2 Nanoparticle surface
Nanoparticles have a very large surface area compared to the size of the 
nanoparticle and compared to normal particles, and this space provides a high 
degree of interaction with the molecule and its environment, and of course it is 
possible to almost determine the final fate of the nanoparticle inside the body 
through determining the strength of the interaction between the nanoparticle and 
its surroundings, and it depends largely on a mixture of size. And surface proper-
ties. Nanoparticles that are sterically stabilized polymers on their surface and have 
surface charges that are either slightly negative or slightly positive tend to have 
minimal self–self and self–non-self-interactions, Nanoparticles often have unex-
pected visible properties because they are small enough to confine their electrons 
and produce quantum effects. This provides a tremendous driving force for diffu-
sion, especially at elevated temperatures [31, 32].
Figure 2. 
Basic nanoparticles used in clinical trials. (a) Nanoparticles composed of therapeutic components. (b) the 
nanoparticles that are formed from polymer/drug. (c) Nanoparticles that are a liposome component.
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5.3 Nano-chemical therapeutics
The rare properties of nanoparticles have been exploited to present the science 
of chemical therapeutics in a unique way and as we previously knew that nanopar-
ticles and the reason for their special composition can exploit the vascular infusion 
and absorption mechanisms associated with tumor cells to enter and implement a 
specific therapeutic effect where the particles accumulate in the tumor tissue, tak-
ing advantage of the enhanced permeability and retention effect, of course, when 
comparing the usual systemic chemotherapy by systemic administration with the 
science of chemotherapy coated with nanoparticles, where it can deliver the desired 
dose to the tissue environment of the tumor. In almost the same way, special bonds 
to cancer cells are added to nanoparticles to arrive in a uniform and targeted way to 
reduce the toxicity of systemic chemotherapy, we will mention the most common 
therapeutics [33].
A present example is a (PEGylated liposomal doxorubicin) formulation that 
has been.
U.S. Food and Drug Administration (FDA) approved for use in recurrent and 
platinum-resistant cancers (Figure 4) [34].
We previously knew that the liposomes remain less time in the circulatory 
system, and this affects the drug levels that reach the tumor tissue, and this can be 
bypassed by reducing the size of the carrier, but this may affect the levels of the 
drug and its required quantity, so to get rid of problems, the carrier is coated with 
polymers such as polyethylene glycol (PEG). As this system works to mask the 
immune system and increase circulation time [35]. The proposed mechanism of 
action and accumulation of DOXIL is as follows:
The liposomes coated with doxoribicin remain in circulation for 2–3 weeks after 
the injection process until the end of their estimated effective life, these particles 
enter the tumor tissue and settle in it through defects and gaps in the tumor vessels 
and then settle near the blood vessel, The extravasated liposomes release the drug 
Figure 3. 
The idea of special targeting of cancer cells to the nanoparticles that can be filtered through the kidney. As the 
nanoparticles target cancerous diseases, the residue that is not targeted is removed.
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components, and drug molecules enter deeply into the tumor tissue, where they 
reach and kill cancer cells. It is noted that this mechanism does not need a physical 
encounter and contact between the liposome and the cell, where the drug can reach 
and penetrate the barriers that intercept the particles [36].
There is another example of a nano-drug transporter (micelle) these structures 
typically contain a more hydrophobic component that helps solubilize/encapsulate 
therapeutic compounds, while a hydrophilic component provides stability of the 
assembly in aqueous environments and offers conjugation sites for eventual target-
ing ligands. This type of nanostructure has been widely used recently, an example 
being the D-α-tocopheryl polyethylene glycol (PEG) 1000 succinate (TPGS) 
(Figure 5) [37].
It is an amphiphilic water-soluble derivative of natural source vitamin E and 
PEG, that has been widely employed as a micelle-former biomaterial. Also, it has 
been reported that TPGS can inhibit the efflux pump that mediates multidrug 
Figure 4. 
This shape represents a Doxil liposome where doxorubicin is confined and encapsulated in the internal 
compartment where drug molecules are tightly packed.
Figure 5. 
A typical structure of polymeric micelle representing the drug encapsulated and targeting moiety attached.
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resistance in tumor cells, known as P-glycoprotein (P-gp), In this context, TPGS has 
been employed for DOX encapsulation within polymeric micelles, Single polymers 
are the most acceptable type in recent times because they increase the solubility and 
stability of hydrophobic drugs, increase cellular absorption capacity, and to increase 
the susceptibility, two micelles were combined to obtain mixed micelles to increase 
strength. as enhanced thermodynamic and kinetic stabilities, higher drug loading 
(DL) capacity, more accurate size control and easier ways to modify their surface 
with different moieties [38, 39].
6. Conclusion
From the foregoing that nanoparticles are more efficient in the diagnosis and 
treatment of ovarian cancer as a basic alternative to chemotherapy and a highly 
efficient pre and postoperative adjuvant due to their great ability to reach the target 
tissue and high efficiency to stay in vivo for acceptable periods.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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